Castle Biosciences Inc（CSTL）の財務CSTLCastle Biosciences Inc

Evaluating the bottom line, Castle Biosciences, Inc. maintains a gross margin of 74.94%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.96%, while the net margin is -1.99%. These profitability ratios, combined with a Return on Equity (ROE) of -4.20%, provide a clear picture of how effectively CSTL converts its operational activities into shareholder value.

In the context of the broader market, CSTL competes directly with industry leaders such as CBLL and PRCT. With a market capitalization of $1.00B, it holds a significant position in the sector. When comparing efficiency, CSTL's gross margin of 74.94% stands against CBLL's 92.32% and PRCT's 66.01%. Such benchmarking helps identify whether Castle Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 74.94% in Q2 2026, indicating strong profitability potential despite recent losses. Revenue guidance for 2026 was raised to $365 million-$375 million, reflecting positive growth expectations.